Recommendations for screening and detection of connective-tissue disease associated pulmonary arterial hypertension.
Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, Fitzgerald J, McLaughlin V.
Arthritis Rheum. 2013 Dec;65(12):3194-201. doi: 10.1002/art.38172.
Recommendations for screening and detection of connective-tissue disease associated pulmonary arterial hypertension.
Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, Fitzgerald J, McLaughlin V.
University of Michigan, Ann Arbor, MI, USA.
Abstract
Objectives: Pulmonary arterial hypertension (PAH) affects up to 15% of patients with connective tissue diseases (CTD). Previous recommendations developed as part of larger efforts in PAH did not provide detailed recommendations for patients with CTD-PAH. Therefore, we sought to develop recommendations for screening and early detection of CTD-PAH. Methods: We performed a systematic review for the screening and diagnosis of PAH in CTD by searching the literature. Using the RAND/UCLA methodology, we developed case scenarios followed by 2 stages of voting-first international experts from a variety of specialties voted anonymously on the appropriateness of each case scenario and then the experts met in a face-to-face meeting to discuss and resolve discrepant votes to arrive at consensus recommendations. Results: The key recommendations state that patients with systemic sclerosis (SSc) should be screened for PAH. In addition, mixed connective tissue diseases (MCTD) or other CTD's with scleroderma features should also be screened for PAH (scleroderma-spectrum disorder). Initial screening evaluation in patients with SSc and scleroderma-spectrum disorders include pulmonary function test (PFT) including diffusion capacity carbon monoxide (DLCO), transthoracic echocardiogram (TTE), and NT- Pro BNP. In SSc and spectrum disorders, TTE and PFT should be performed on annual basis. The full screening panel (TTE, PFT, and NT-ProBNP) should be performed as soon as any new signs or symptoms are present. Conclusion: We provide consensus-based, evidence-driven recommendations for screening and early detection of CTD-PAH. It is our hope that these recommendations will lead to earlier detection of CTD-PAH and ultimately improve patient outcomes. © 2013 American College of Rheumatology.
Copyright © 2013 American College of Rheumatology.
PMID:24022584
Inflammatory Mechanisms in HIV-Associated Pulmonary Arterial Hypertension.
Tcherakian C, Couderc LJ, Humbert M, Godot V, Sitbon O, Devillier P.
Idiopathic pulmonary arterial hypertension.
Souza R, Jardim C, Humbert M.
Current challenges in pulmonary hypertension.
Humbert M.
Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension.
Trip P, Girerd B, Bogaard HJ, de Man FS, Boonstra A, Garcia G, Humbert M, Montani D, Vonk-Noordegraaf A.
Right Ventricular Diastolic Impairment in Patients with Pulmonary Arterial Hypertension.
Rain S, Handoko ML, Trip P, Gan TJ, Westerhof N, Stienen G, Paulus WJ, Ottenheijm C, Marcus JT, Dorfmüller P, Guignabert C, Humbert M, Macdonald P, Dos Remedios C, Postmus PE, Saripalli C, Hidalgo CG, Granzier HL, Vonk-Noordegraaf A, van der Velden J, de Man FS.
Outcome of full-thickness chest wall resection for isolated breast cancer recurrence.
Levy Faber D, Fadel E, Kolb F, Delaloge S, Mercier O, Mussot S, Fabre D, Dartevelle P.
Endothelin Receptor Antagonists.
Clozel M, Maresta A, Humbert M.
Definition and Classification of Pulmonary Hypertension.
Humbert M, Montani D, Evgenov OV, Simonneau G.
Calcium-channel blockers in pulmonary arterial hypertension.
Chaumais MC, Macari EA, Sitbon O.